

Faculty

Ebaa Al Ozairi - *Dasman Institute Kuwait*

Luigi Angrisani - *University Federico II Naples Italy*

Nicola Basso - *University Sapienza Rome Italy*

Stefan Bornstein - *Transcampus Dean Dresden/London*

Lutgarda Bozzetto - *University Federico II Naples Italy*

Silvio Buscemi - *University of Palermo*

Esmeralda Capristo - *Università Cattolica S. Cuore Rome Italy*

Giovanni Casella - *University Sapienza Rome Italy*

Lidia Castagneto Gissei - *Università La Sapienza, Roma*

Maurizio De Luca - *Rovigo, Italy*

Tristano Della Corte - *Rome, Italy*

Nicola Di Lorenzo - *University Sapienza Rome Italy*

Josè Manuel Fernandez - *Real University of Girona Spain*

Amalia Gastaldelli - *National Council of Research Pisa Italy*

Alexander Kokkinos - *University of Athens Greece*

Martine Laville - *University Claude - Bernard, Lyon*

Andrea Lenzi - *University Sapienza Rome Italy*

Melania Manco - *Ospedale Pediatrico Bambin Gesù' Rome Italy*

Geltrude Mingrone - *Università Cattolica S. Cuore Rome Italy*

Mario Musella - *University Federico II Naples Italy*

Philip Newsome - *King's College London UK*

Francois Pattou - *University of Lille France*

Marco Raffaelli - *Università Cattolica S. Cuore Rome Italy*

Stefano Romeo - *Karolinska University Stockholm Sweden*

Francesco Rubino - *King's College London UK*

Giorgio Sesti - *University Sapienza Rome Italy*

Roberto Vettor - *Humanitas, Milan, Italy*

Antonio Vidal Puig - *Cambridge University UK*

We thank for the non-conditioning contribution



CALL FOR ABSTRACTS

Abstract submission is now open! Don't miss the opportunity to present your research
Deadline: October 30, 2025

INSTRUCTIONS

Abstracts must clearly and completely describe the objectives and results of the work.

They will be evaluated based on:

- Originality
- Study quality
- Completeness of the work

Requirements: Language: English

CHARACTER LIMIT

The abstract must not exceed 250 words (Title, authors, and affiliations are excluded from the count.)

The abstract must include the following sections: Background, Methods, Results, Conclusions

By submitting an abstract you accept to share your work either as a poster or oral presentation. The Scientific Committee will designate the format (oral or poster). The final acceptance decision is the exclusive right of the Scientific Committee.

**SUBMIT
YOUR ABSTRACT HERE**



The Conference is accredited by **AGE.NA.S.** (National Agency for Regional Health Services) under the number **5357 - 459514**, and grants **12** Continuing Medical Education (CME) credits.

Online registration is free of charge and must be completed through the website: **www.bleassociates.it**

To obtain CME credits, it is mandatory to register at the **Organizing Secretariat desk** on the day of the event, and to collect the **congress kit** and the required **ECM documentation**.
Punctual attendance is strongly recommended.
Participants arriving **more than 15 minutes** after the scheduled registration time will be admitted to the conference room **as listeners only**, and will **not be eligible for CME credits**.

CME credits will be awarded **only upon**:
Verified attendance for at least **90%** of the total event duration;
Completion and successful passing of the final assessment questionnaire.
The **CME certificate** will be sent via **email** to the address provided at the time of registration, starting from **February 27, 2026**.
The **certificate of attendance** may be collected at the **Organizing Secretariat desk**, upon **return of the congress badge**.

Participants are also invited to review the AGE.NA.S. privacy policy, available at:
<https://ecm.agenas.it/privacy-policy>



PROVIDER ORGANIZATIONAL SECRETARIAT
ble&associates s.r.l.
p.: **0823 30.16.53**
f.: **0823 36.10.86**
e.: **segreteria@bleassociates.it**
www.bleassociates.it

**TO REGISTER
SCAN THE QR CODE**



Advancing Obesity and Metabolic Disease Research: *from pathophysiology to innovative treatments*

Naples, 27-28 November 2025

Royal Continental Hotel

Scientific Committee: Prof. Geltrude Mingrone



Scientific Rationale

Obesity and its related metabolic disorders remain some of the most pressing public health challenges of our time, requiring a multidisciplinary approach to understand their pathophysiology, clinical implications, and treatment strategies. This meeting brings together experts from various fields to provide a comprehensive overview of obesity, metabolic dysfunction-associated steatotic liver disease (MASLD), and their interconnections with metabolic and cardiovascular health.

The meeting begins with an introduction, setting the stage for discussions that blend scientific insights with broader reflections on competition and perseverance, as illustrated by the historical rivalry between Bernini and Borromini. This thematic introduction serves as a metaphor for scientific progress, emphasizing the importance of collaboration and innovation in advancing medical research.

A key focus of the meeting is the dysfunction of adipose tissue and its impact on obesity and liver health. The presentation on this topic provides a foundation for understanding the mechanisms driving metabolic diseases, setting the stage for subsequent discussions on MASLD/MASH pathophysiology. Given the increasing prevalence of metabolic-associated liver disease, emerging insights into its underlying mechanisms and new diagnostic and treatment strategies are crucial.

The second day begins with discussions on the distinction between clinical and preclinical obesity, an evolving concept that has significant implications for both treatment and prevention. Clarifying these definitions is essential for refining diagnostic criteria, identifying individuals at risk, and implementing targeted interventions. The prevalence of these obesity subtypes will be explored, followed by a round table discussion where experts will debate the most effective approaches for diagnosing and managing clinical obesity.

Pharmacological treatment remains a cornerstone of obesity management, and recent advancements in weight loss medications warrant a dedicated session to provide a comprehensive overview of their efficacy, safety, and place in therapy. Additionally, obesity in type 1 diabetes a less frequently discussed but clinically significant condition will be examined to shed light on its prevalence and treatment implications.

Bariatric surgery continues to play a pivotal role in obesity management, even as pharmacological approaches advance. The evolving relationship between surgery and medication-based treatments will be explored, with a focus on optimizing patient outcomes. Furthermore, MASLD/MASH will be examined from both hepatic and cardiometabolic perspectives, emphasizing the need for tailored treatment strategies based on disease subtypes.

The meeting will also highlight novel insights into the role of leptin deficiency and leptin receptor defects in insulin resistance and diabetes, further expanding our understanding of obesity-related metabolic dysfunction. Finally, the conference will address the cardiovascular benefits of GLP-1 receptor agonists, reinforcing their role beyond glucose control in the secondary prevention of cardiovascular events.

By fostering discussions across disciplines including endocrinology, hepatology, pharmacology, and bariatric surgery this meeting aims to drive innovation in obesity research, refine diagnostic and therapeutic strategies, and ultimately improve patient care. The concluding remarks will summarize key takeaways and outline future directions for research and clinical practice.

27.11.2025

13:30 Welcome and meeting introduction
Geltrude Mingrone

14:00 The Pompei Tales: misteries, miseries and mischiefs
Nicola Basso

14:30 Coffee Break

Chairmen: Maurizio De Luca, Roberto Vettor

14:45 The Impact of Adipose Tissue Dysfunction on Obesity and Liver Health
Antonio Vidal Puig

15:15 Will OMMs replace Metabolic Bariatric Surgery?
Lidia Castagneto Gissey

16:30 Weight loss medications an overview
Ebaa Al Ozairi

17:00 Obesity Care in France: Organization, Implementation, and the New National Roadmap
Martine Laville

17:30 Oral communications
Moderator: Lidia Castagneto Gissey

19:30 Take Home messages

28.11.2025

Chairmen: Andrea Lenzi, Geltrude Mingrone

08:30 Round table on pharmacological approaches to Obesity treatment in Italy and National Health System
Francesco Rubino, Roberto Vettor, Tristano Della Corte

Chairmen: Giorgio Sesti

09:00 Clinical and PreClinical Obesity: implications for obesity treatment and prevention
Francesco Rubino

09:30 Prevalence of Clinical and PreClinical Obesity
Josè Manuel Fernandez

10:00 Round table on Clinical Obesity diagnosis
Chairman: Nicola Di Lorenzo
Discussants: Francesco Rubino, Marco Raffaelli, Martine Laville, Silvio Buscemi

11:00 Coffee Break

Chairmen: Giovanni Casella, Mario Musella

11:30 Treat to target in obesity
Francois Pattou

12:00 Secondary prevention of cardiovascular events with GLP1- RAs
Alexander Kokkinos

12:30 Oral Communications
Moderator: Lutgarda Bozzetto

13:00 Lunch

Chairman: Luigi Angrisani

14:15 Prevalence of obesity in childhood and adolescence and treatment
Melania Manco

14:45 Liver-Specific MASH vs Cardiometabolic MASH
Stefano Romeo

15:15 Present and near future of MASH diagnosis and treatment
Philip Newsome

15:45 Decoding the pathophysiology of MASLD/MASH: emerging insights
Amalia Gastaldelli

16:15 Coffee Break

Chairman: Esmeralda Capristo

16:45 Oral Communications
Moderator: Lutgarda Bozzetto

17:15 Diabetes and obesity and infectious susceptibility
Stefan Bornstein

17:45 Conclusive remarks
Geltrude Mingrone